DINUCLEOSIDE-5',5'-PYROPHOSPHATES
    2.
    发明授权
    DINUCLEOSIDE-5',5'-PYROPHOSPHATES 失效
    二核苷-5' ,5'-焦磷酸盐

    公开(公告)号:EP0773951B1

    公开(公告)日:1999-03-10

    申请号:EP95943516.5

    申请日:1995-07-10

    IPC分类号: C07H21/00 A61K31/70

    CPC分类号: C07H21/00

    摘要: 5',5'-Pyrophosphates of non-naturally occurring nucleosides selected from thymine-3'-azido-2',3'-dideoxy-D-riboside, 5-fluorouracil-2'-deoxy-D-riboside, uracil-3'-azido-2',3'-dideoxy-D-riboside, guanine-2',3'-dideoxy-D-riboside, hypoxanthine-2',3'-dideoxy-D-riboside, cytosine-2',3'-dideoxy-D-riboside, and adenine-2',3'-dideoxy-D-riboside, are described as well as their manufacture and use as therapeutical agents against tumors and retroviral infections including HIV infections. The compounds may be administered as the active ingredients of pharmaceutical compositions or as pro-drugs encapsulated into biological carriers, e.g., transformed erythrocytes, for targeting to specific cell population responsible of the development of the pathological disorders.

    摘要翻译: 选自胸腺嘧啶-3'-叠氮基-2',3'-二脱氧-D-核糖核苷,5-氟尿嘧啶-2'-脱氧-D-核糖苷,尿嘧啶-3的非天然存在的核苷的5',5'-焦磷酸酯 ' - 叠氮基-2',3'-双脱氧-D-核糖苷,鸟嘌呤-2',3'-双脱氧-D-核糖苷,次黄嘌呤-2',3'-双脱氧-D-核糖苷,胞嘧啶-2',3 ' - 双脱氧-D-核糖苷和腺嘌呤-2',3'-双脱氧-D-核糖苷以及它们的制造和用作抗肿瘤和包括HIV感染在内的逆转录病毒感染的治疗剂。 所述化合物可作为药物组合物的活性成分或作为封装到生物载体(例如转化的红细胞)中的前药施用以靶向导致病理性疾病发展的特定细胞群。

    DINUCLEOSIDE-5',5'-PYROPHOSPHATES
    6.
    发明公开
    DINUCLEOSIDE-5',5'-PYROPHOSPHATES 失效
    DINUKLEOSID-5',5'-磷酸氢钙

    公开(公告)号:EP0773951A1

    公开(公告)日:1997-05-21

    申请号:EP95943516.0

    申请日:1995-07-10

    CPC分类号: C07H21/00

    摘要: 5',5'-Pyrophosphates of non-naturally occurring nucleosides selected from thymine-3'-azido-2',3'-dideoxy-D-riboside, 5-fluorouracil-2'-deoxy-D-riboside, uracil-3'-azido-2',3'-dideoxy-D-riboside, guanine-2',3'-dideoxy-D-riboside, hypoxanthine-2',3'-dideoxy-D-riboside, cytosine-2',3'-dideoxy-D-riboside, and adenine-2',3'-dideoxy-D-riboside, are described as well as their manufacture and use as therapeutical agents against tumors and retroviral infections including HIV infections. The compounds may be administered as the active ingredients of pharmaceutical compositions or as pro-drugs encapsulated into biological carriers, e.g., transformed erythrocytes, for targeting to specific cell population responsible of the development of the pathological disorders.